[Correspondence] Primary medical therapy for BRAFV600E-mutant melanoma brain metastases—is this good enough?

We applaud Michael A Davies and colleagues1 for their phase 2 study evaluating the role of dabrafenib plus trametinib in BRAFV600E-mutant melanoma brain metastases. While this well conducted study shows clinical activity (58% achieved an intracranial response) of this combination, we urge caution in the interpretation of this study, and reconsideration of similar forthcoming study designs.

http://ift.tt/2eNqrax